• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Edgewise

Edgewise Therapeutics

A Movement in Muscle

  • Clinical Trials
  • Careers
  • Investors & News
  • Company
    • Company Overview
    • Leadership Team
    • Careers
    • Contact Us

    We are dedicated to transforming cardiovascular muscle diseases.

    Learn More

  • Science
    • Pipeline
    • EDG-7500
    • EDG-15400
    • Clinical Trials
    • Posters & Presentations

    All of us at Edgewise are committed to developing new medicines for people facing serious cardiovascular diseases with unmet medical needs.

    Explore our Pipeline

  • Disease Areas
    • Cardiovascular Diseases
    • Muscular Dystrophy & Sevasemten

    Servier Acquires Our Muscular Dystrophy Program

    Following the close of our transaction with Servier, Edgewise’s muscular dystrophy business, including sevasemten, is now part of Servier. Servier’s global capabilities and commitment to neuromuscular diseases position it to advance sevasemten and continue supporting the patient and advocacy communities we have been privileged to serve.

    Edgewise is now focused exclusively on advancing high-impact therapies for people living with serious cardiovascular diseases.

    Learn more

  • Patients & Families
  • Investors & News
    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Governance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts
Home Company Leadership Team Michael Nofi

Michael Nofi

Chief Financial Officer

Michael Nofi has served as our Chief Financial Officer since November 2025. Most recently Mr. Nofi served as Chief Accounting Officer of SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, where he led the company from its IPO, commercial transformation, and acquisition by Merck KGaA. Prior to SpringWorks, he was Chief Accounting Officer and Vice President of Global Accounting and Corporate FP&A at The Nature’s Bounty Co. Mr. Nofi also held senior finance roles at Acorda Therapeutics, Allergan plc, and Forest Laboratories, where he led integration efforts across multiple acquisitions. Earlier in his career, he served as a Senior Manager at PricewaterhouseCoopers, LLP. Mr. Nofi holds a B.S. in accounting and an M.B.A. from Villanova University and is a Certified Public Accountant.

  • Meet our leadership team
  • Meet our board of directors

Footer

Edgewise Therapeutics
  • Company
  • Science
  • Disease Areas
  • Patients & Families
  • Investors & News

In the Clinic

We are advancing novel precision therapeutics for serious cardiovascular disease.

Explore our pipeline

2026 © Copyright. Edgewise Therapeutics. All Rights Reserved.

  • Privacy Policy
  • Terms of Use
Facebook X, formally Twitter LinkedIn Instagram YouTube
logo
  • Company
    • Leadership Team
    • Careers
    • Contact Us
  • Science
    • Pipeline
    • EDG-7500
    • EDG-15400
    • Clinical Trials
    • Posters & Presentations
  • Disease Areas
    • Cardiovascular Diseases
    • Muscular Dystrophy & Sevasemten
  • Patients & Families
  • Investors & Media
    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Goverance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts